Novartis’ slow-rolling Kymriah wins coverage in Japan at $305K: report
admin 15th May 2019 Uncategorised 0After snagging the first Japanese CAR-T approval in March, Novartis has won the go-ahead to sell its groundbreaking drug, Kymriah, under the country’s national insurance system. And that gives the brand a chance to boost lagging sales.
More: Novartis’ slow-rolling Kymriah wins coverage in Japan at 5K: report
Source: fierce